Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2409946 | Vaccine | 2006 | 8 Pages |
Abstract
The HIV-1 matrix protein p17 is a structural protein essential in the life cycle of HIV, by acting as a virokine/immunomodulator that supports viral replication and spreading. The presence of p17-specific antibodies and CTL responses correlates with slower progression to AIDS. Intranasal vaccination with p17 and the TLR2/6 agonist MALP-2 stimulates strong humoral and cellular immune responses at systemic and mucosal levels. The antibodies blocked p17 binding to its receptor, which is a critical step for the exertion of its virokine activity. Our results suggest that p17 and MALP-2 are attractive candidates for incorporation in mucosal vaccines against HIV/AIDS.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Pablo D. Becker, Simona Fiorentini, Claudia Link, Giorgio Tosti, Thomas Ebensen, Arnaldo Caruso, Carlos A. Guzmán,